Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population

Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast

(2015) Mu-Min Shao et al.   HISTOPATHOLOGY

Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer

(2014) Chenguang Li et al.   PLoS One

Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells

(2013) Maira M. Pires et al.   CANCER BIOLOGY & THERAPY

Targeting triple negative breast cancer: Is p53 the answer?

(2013) Natalie Turner et al.   CANCER TREATMENT REVIEWS

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

(2012) Tobias J. Grob et al.   BREAST CANCER RESEARCH AND TREATMENT

Distincttumor protein p53mutants in breast cancer subgroups

(2012) Anne Dumay et al.   INTERNATIONAL JOURNAL OF CANCER

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer

(2012) Yiqing Tang et al.   Journal of Translational Medicine

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of triple negative breast cancer

(2010) Catherine Oakman et al.   BREAST

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

(2010) Lisa Rydén et al.   BREAST CANCER RESEARCH AND TREATMENT

EGFR expression and gene copy number in triple-negative breast carcinoma

(2010) Berrak Gumuskaya et al.   CANCER GENETICS AND CYTOGENETICS

Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer

(2010) Monika L. Burness et al.   CANCER JOURNAL

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

(2009) B. Corkery et al.   ANNALS OF ONCOLOGY

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

(2008) Giuseppe Viale et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

(2008) N. Personeni et al.   CLINICAL CANCER RESEARCH

How basal are triple-negative breast cancers?

(2008) François Bertucci et al.   INTERNATIONAL JOURNAL OF CANCER